■分析CO2点阵激光联合复方倍他米松治疗白癜风的临床疗效及对炎症因子的影响。
■临床治疗效果,炎症因子水平[白细胞介素-17(IL-17),干扰素-γ(IFN-γ),白细胞介素-10(IL-10)],关于色素沉着和复发的预后,心理健康(满意度)。
■①临床治疗效果:A组总有效率为92.73%,B组为74.55%,C组为67.27%,A组的有效性明显高于B组和C组(p<0.05)。②炎症因子:治疗前,IL-17、IFN-γ、和IL-10水平在三组之间(p>0.05);治疗3、6个月后,在所有三组中,IL-17和IFN-γ的水平显着降低,而IL-10水平显着升高,与B和C组相比,A组显示出更显著的变化(p<0.05)。③关于色素沉着和复发的预后:治疗3个月和6个月后,A组表现出显著高于B组和C组(p<0.05);在复发方面,A组复发率为5.45%,B组有21.82%,C组为23.64%,与B和C组相比,A组的复发率显着降低(p<0.05)。④生活质量和心理健康:6个月随访结束时,A组患者的生活质量和心理健康状况明显高于B组和C组(p<0.05)。⑤不良反应发生情况:A组不良反应发生率为12.73%,B组10.91%,丙组9.09%,三组间无显著差异(p>0.05)。
■CO2点阵激光联合复方倍他米松治疗白癜风疗效显著。与CO2点阵激光或复方倍他米松注射液单独治疗相比,这种联合方法进一步改善了白癜风患者的炎症因子水平,降低复发的风险,增强皮肤色素沉着,提高生活质量,心理健康,不会增加相关不良反应的风险。这种联合方法值得临床推广应用。
UNASSIGNED: To analyze the clinical efficacy of CO2 fractional laser combined with compound betamethasone in treating vitiligo and its impact on inflammatory factors.
UNASSIGNED: The clinical treatment effects, levels of inflammatory factors [interleukin-17 (IL-17), interferon-gamma (IFN-γ), interleukin-10 (IL-10)], prognosis regarding repigmentation and relapse, psychological health (satisfaction).
UNASSIGNED: ① Clinical treatment effects: the total effective rate in Group A was 92.73%, Group B was 74.55%, and Group C was 67.27%, with Group A showing significantly higher effectiveness than Groups B and C (p < 0.05). ② Inflammatory factors: prior to treatment, there was no significant difference in IL-17, IFN-γ, and IL-10 levels among the three groups (p > 0.05); after 3 and 6 months of treatment, the levels of IL-17 and IFN-γ decreased significantly while IL-10 levels increased significantly across all three groups, with Group A showing a more pronounced change compared to Groups B and C (p < 0.05). ③ Prognosis regarding repigmentation and relapse: after 3 and 6 months of treatment, Group A exhibited significantly higher repigmentation rates compared to Groups B and C (p < 0.05); in terms of relapse, Group A had a relapse rate of 5.45%, Group B had 21.82%, and Group C had 23.64%, with Group A showing significantly lower relapse rates compared to Groups B and C (p < 0.05). ④ Quality of life and psychological health: at the end of the 6 month follow-up, the quality of life and psychological health of patients in Group A were significantly higher than those in Groups B and C (p < 0.05). ⑤ Occurrence of adverse reactions: the incidence of adverse reactions was 12.73% in Group A, 10.91% in Group B, and 9.09% in Group C, with no significant difference observed among the three groups (p > 0.05).
UNASSIGNED: The application of CO2 fractional laser combined with compound betamethasone in vitiligo patients demonstrates significant efficacy. Compared to sole treatment with CO2 fractional laser or compound betamethasone injections, this combined approach further improves the levels of inflammatory factors in vitiligo patients, reduces the risk of relapse, enhances skin repigmentation, improves quality of life, psychological well-being, without increasing the risk of related adverse reactions. This combined approach merits clinical promotion and application.